Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2015 2
2016 1
2017 6
2018 6
2019 2
2020 4
2021 8
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Investigational drugs for T-cell lymphoma.
Ghez D, Danu A, Ribrag V. Ghez D, et al. Among authors: danu a. Expert Opin Investig Drugs. 2016;25(2):171-81. doi: 10.1517/13543784.2016.1121994. Epub 2015 Dec 17. Expert Opin Investig Drugs. 2016. PMID: 26576861 Review.
[Hodgkin lymphoma: Current and future therapeutic strategies].
Turpin A, Michot JM, Kempf E, Mazeron R, Dartigues P, Terroir M, Boros A, Bonnetier S, Castilla-Llorente C, Coman T, Danu A, Ghez D, Pilorge S, Arfi-Rouche J, Dercle L, Soria JC, Carde P, Ribrag V, Fermé C, Lazarovici J. Turpin A, et al. Among authors: danu a. Bull Cancer. 2018 Jan;105(1):81-98. doi: 10.1016/j.bulcan.2017.11.008. Epub 2017 Dec 27. Bull Cancer. 2018. PMID: 29289336 Review. French.
Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
Michot JM, Lazarovici J, Ghez D, Danu A, Fermé C, Bigorgne A, Ribrag V, Marabelle A, Aspeslagh S. Michot JM, et al. Among authors: danu a. Eur J Cancer. 2017 Nov;85:67-77. doi: 10.1016/j.ejca.2017.08.014. Epub 2017 Sep 9. Eur J Cancer. 2017. PMID: 28892775 Review.
Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study.
Michot JM, Quivoron C, Sarkozy C, Danu A, Lazarovici J, Saleh K, El-Dakdouki Y, Goldschmidt V, Bigenwald C, Dragani M, Bahleda R, Baldini C, Arfi-Rouche J, Martin-Romano P, Tselikas L, Gazzah A, Hollebecque A, Lacroix L, Ghez D, Vergé V, Marzac C, Cotteret S, Rahali W, Soria JC, Massard C, Bernard OA, Dartigues P, Camara-Clayette V, Ribrag V. Michot JM, et al. Among authors: danu a. Am J Hematol. 2023 Apr;98(4):645-657. doi: 10.1002/ajh.26835. Epub 2023 Jan 18. Am J Hematol. 2023. PMID: 36606708 Free article.
Eltrombopag in adult patients with immune thrombocytopenia in the real-world in France, including off-label use before 6 months of disease duration: The multicenter, prospective ELEXTRA study.
Moulis G, Germain J, Rueter M, Lafaurie M, Aroichane M, Comont T, Mahévas M, Viallard JF, Chèze S, Ebbo M, Audia S, Leclerc-Teffahi S, Sommet A, Beyne-Rauzy O, Michel M, Godeau B, Lapeyre-Mestre M; CARMEN investigators group. Moulis G, et al. Am J Hematol. 2022 Feb 1;97(2):E40-E44. doi: 10.1002/ajh.26404. Epub 2021 Dec 6. Am J Hematol. 2022. PMID: 34779031 Free PMC article. No abstract available.
Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphoma.
Quivoron C, Tarabay A, Michot JM, Pagès A, Lecourt H, Aupérin A, Danu A, Lazarovici J, Rossignol J, Ghez D, Dartigues P, Vergé V, Massard C, Camara-Clayette V, Ribrag V, Sarkozy C. Quivoron C, et al. Among authors: danu a. Haematologica. 2022 Aug 1;107(8):1928-1932. doi: 10.3324/haematol.2021.280464. Haematologica. 2022. PMID: 35320922 Free PMC article. No abstract available.
Reduced frequency of cytotoxic CD56dim CD16+ NK cells leads to impaired antibody-dependent degranulation in EBV-positive classical Hodgkin lymphoma.
Pánisová E, Lünemann A, Bürgler S, Kotur M, Lazarovici J, Danu A, Kaulfuss M, Mietz J, Chijioke O, Münz C, Busson P, Berger C, Ghez D, Azzi T. Pánisová E, et al. Among authors: danu a. Cancer Immunol Immunother. 2022 Jan;71(1):13-24. doi: 10.1007/s00262-021-02956-x. Epub 2021 May 15. Cancer Immunol Immunother. 2022. PMID: 33993319 Free PMC article.
Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 study.
Sarkozy C, Michot JM, Quivoron C, Camara-Clayette V, Danu A, Lazarovici J, El-Dakdouki Y, Saleh K, Ghez D, Rossignol J, Baldini C, Arfi-Rouche J, Romano-Martin P, Tselikas L, Varga A, Gazzah A, Hollebecque A, Lacroix L, Bahleda R, Lecourt H, Vergé V, Rahali W, Cotteret S, Soria JC, Dartigues P, Massard C, Ribrag V. Sarkozy C, et al. Among authors: danu a. Am J Hematol. 2021 Oct 1;96(10):E376-E379. doi: 10.1002/ajh.26280. Epub 2021 Jul 10. Am J Hematol. 2021. PMID: 34165816 Free article. Clinical Trial. No abstract available.
Post-shingles granulomatous dermatosis related to anti-programmed cell death 1.
Assi T, Danu A, Mateus C, Robert C, Michot JM, Ibrahim T, Lazarovici J, Ghez D, Rossignol J, Dartigues P, Terroir-Cassou-Mounat M, Ribrag V. Assi T, et al. Among authors: danu a. Immunotherapy. 2019 May;11(7):591-598. doi: 10.2217/imt-2018-0169. Immunotherapy. 2019. PMID: 30943861
27 results